About Omacetaxine
            
            Class: | Antineoplastic agent, protein synthesis inhibitor  
Use: | Treatment of adult patients with chronic myeloid leukemia (CML) who are resistant to or intolerant of two or more tyrosine kinase inhibitors  
Adult dose: | Initial dose of 1.25 mg/m² subcutaneously twice daily for 14 days, followed by a 7-day treatment-free interval; may repeat cycles based on clinical response  
Pediatric dose: | Safety and efficacy have not been established in pediatric patients  
Side effects: | Common side 
         
        
            
                
                
                    
                        Drug Class
                    
                    Antineoplastic agent, protein synthesis inhibitor
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adult patients with chronic myeloid leukemia (CML) who are resistant to or intolerant of two or more tyrosine kinase inhibitors
                 
                
                
                    
                        Storage Requirements
                    
                    Store at 20°C to 25°C (68°F to 77°F); protect from light; do not freeze
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Teva Pharmaceuticals, U.S.A
                    
                    
                    Package Size
                    1 Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 5893.75
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose of 1.25 mg/m² subcutaneously twice daily for 14 days, followed by a 7-day treatment-free interval; may repeat cycles based on clinical response
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy have not been established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include injection site reactions, nausea, diarrhea, fatigue, thrombocytopenia, neutropenia, and anemia
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to omacetaxine or any component of the formulation; caution in patients with a history of bleeding disorders or severe hepatic impairment
         
        
        
            
                Important Warnings
            
            Risk of myelosuppression, including thrombocytopenia, neutropenia, and anemia; monitor blood counts regularly; potential for serious infections; use caution in patients with hepatic impairment
         
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.